Document is current
Any future updates will be listed below
-
Authors
Martin-Broto, Javier https://orcid.org/0000-0001-7350-6916
Casado, Antonio
Marquina, Gloria https://orcid.org/0000-0002-8961-9787
Redondo, Andres
Martinez-Trufero, Javier
Valverde, Claudia
Gutierrez, Antonio
Bernabeu, Daniel https://orcid.org/0000-0003-0828-9104
Ortega, Luis
Merino, Jose
Ramos, Rafael
Ledesma, Patricio
Mondaza-Hernandez, Jose L.
Moura, David S.
Hindi, Nadia https://orcid.org/0000-0002-5864-762X
-
Funding
Funding for this research was provided by:
Karyopharm Therapeutics (NA)
- License Information
-
More Information
Article History
Received: 1 June 2025
Accepted: 13 January 2026
First Online: 20 January 2026
Competing interests
: Javier Martin-Broto has received honoraria for consulting or advisory board participation and expert testimony from PharmaMar, Bayer, GSK, Deciphera, Boehringer Ingelheim, Cogent Biosciences, Roche, Tecnofarma and Asofarma; and research funding for clinical studies (institutional) from Deciphera, PharmaMar, Eli Lilly and Company, BMS, Pfizer, Boehringer Ingelheim, Synox, ABBISKO, Biosplice, Lixte, Karyopharm, Rain Therapeutics, INHIBRX, Immunome, Philogen, Cebiotex, PTC Therapeutics, Inc. and SpringWorks therapeutics. Gloria Marquina has received financial support for advisory board participation: Pharmamar, Clovis oncology, GSK/Tesaro, Lilly, Pfizer, Boehringer Ingelheim, Deciphera, EISAI; lectures: Roche, AstraZeneca, GSK/Tesaro, Clovis Oncology, Medicamenta, EISAI, Pharmamar, Bayer, Lilly, IPSEN, MSD, Inhibrx biosciences INC; and congress attendance: Roche, Pharmamar, GSK/Tesaro, MSD, Medicamenta, Pfizer, Angelini, Novartis, Merck, Lilly, EISAI. Andres Redondo reports receiving honoraria and providing advisory/consultancy services for MSD, AstraZeneca, GSK, Pharma&, and AbbVie, travel/accommodation/congress registration from AstraZeneca and GSK, and participating in a speaker’s bureau for MSD, AstraZeneca, GSK, Pharma& and AbbVie outside the submitted work. David S. Moura has received institutional research grants from PharmaMar and Synox outside the submitted work; travel support from PharmaMar, and personal fees from Tecnopharma, outside the submitted work. Nadia Hindi has received grants, personal fees, and non-financial support from PharmaMar, personal fees from Deciphera, and research funding for clinical studies (institutional) Deciphera, PharmaMar, Eli Lilly and Company, BMS, Pfizer, Boehringer Ingelheim, Synox, ABBISKO, Biosplice, Lixte, Karyopharm, Rain Therapeutics, INHIBRX, Immunome, Philogen, Cebiotex, PTC Therapeutics, Inc. and SpringWorks Therapeutics. The remaining authors declare no competing interests.
